Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting

Phase 1

Phase 2

INBRX-106 & PembrolizumabStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Sponsor:

Inhibrx Biosciences, Inc

Code:

NCT04198766

Conditions

Solid Tumor

Non-Small Cell Lung Cancer

Head and Neck Cancer

Melanoma

Gastric Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INBRX-106 - Hexavalent OX40 agonist antibody

pembrolizumab 200 mg

pembrolizumab 400 mg

Carboplatin AUC-5

Carboplatin AUC-6

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-19. This information was provided to ClinicalTrials.gov by Inhibrx Biosciences, Inc on 2024-07-19.